Autologous Epstein Barr virus-specific adoptive T cell therapy continues to show promise as a novel treatment for patients with progressive MS. In a phase 1 clinical trial in Queensland, EBV-specific T cells were successfully generated from peripheral blood mononuclear cells in 11 of 13 patients with either primary or secondary progressive disease. The two MS ...
EBV immunotherapy improves MS symptoms
By Mardi Chapman
21 Nov 2018